WASHINGTON (AP) The head of the Food and Drug Administration faced congressional lawmakers for the first time Thursday over the shortage of baby formula that has rattled American parents and become a growing political liability for President Joe Biden.

FDA Commissioner Robert Califf’s appearance before a House subcommittee came just hours after Biden announced a stepped-up response to the issue: invoking the Defense Production Act to speed domestic manufacturing and authorizing flights to import formula from overseas.

Califf is the first administration official to testify before Congress on the issue, which has left some parents hunting for formula and become a talking point for Republicans. Behind the shortage are several distinct issues, including supply disruptions caused by the coronavirus pandemic and the recent shutdown of the largest U.S. formula factory.

Earlier this week, the FDA announced several steps to address the problem, including a preliminary agreement with formula maker Abbott Nutrition to reopen its plant, which has been shuttered since February due to contamination.

Members of a House Appropriations subcommittee opened Thursday’s hearing by asking Califf why the FDA didn’t step in last fall when there were signs of problems at Abbott’s plant.

Rep. Rosa DeLauro, D-Conn., pointed to a recently released whistleblower complaint alleging numerous safety violations at Abbott’s plant, including employees falsifying records and failing to properly test formula before releasing it. She said the former Abbott employee alerted the FDA to the situation in October but was not interviewed by agency staff until late December.

``It all begs the question, why did the FDA not spring into action?’’ DeLauro asked, in her opening statement. ``Who in the leadership had access to that report – who didn’t have access to the report – and why was there no reaction?’’

There are other questions about the FDA’s timeline for dealing with Abbott. The company shut its Michigan plant in February after FDA inspectors began investigating four bacterial infections in infants who had consumed formula from the plant. The first of those cases was reported to the FDA in September though agency staff didn’t begin inspecting the facility until late January. Califf said earlier this week the agency’s investigation is ongoing and it hasn’t yet reached a conclusion on whether bacteria from the plant caused the infant infections.

Abbott has said there is no direct evidence linking its products to the illnesses.

On Wednesday evening, House Democrats passed a $28 million spending bill that would boost FDA funding to inspect domestic and international formula producers. It’s fate in the Senate is uncertain.